Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Arthritis Research & Therapy
Published in: Arthritis Research & Therapy 3/2007

01-06-2007 | Review

Arthritis and pain. Future targets to control osteoarthritis pain

Authors: Andy Dray, Simon J Read

Published in: Arthritis Research & Therapy | Issue 3/2007

Login to get access

Abstract

Clinical presentation of osteoarthritis (OA) is dominated by pain during joint use and at rest. OA pain is caused by aberrant functioning of a pathologically altered nervous system with key mechanistic drivers from peripheral nerves and central pain pathways. This review focuses on symptomatic pain therapy exemplified by molecular targets that alter sensitization and hyperexcitability of the nervous system, for example, opioids and cannabinoids. We highlight opportunities for targeting inflammatory mediators and their key receptors (for example, prostanoids, kinins, cytokines and chemokines), ion channels (for example, NaV1.8, NaV1.7 and CaV2.2) and neurotrophins (for example, nerve growth factor), noting evidence that relates to their participation in OA etiology and treatment. Future neurological treatments of pain appear optimistic but will require the systematic evaluation of emerging opportunities.
Appendix
Available only for authorised users
Literature
1.
Bellamy N, Sothern RB, Campbell J: Rhythmic variations in pain perception in osteoarthritis of the knee. J Rheumatol. 1990, 17: 364-372.PubMed
2.
Bellamy N, Sothern RB, Campbell J, Buchanan WW: Rhythmic variations in pain, stiffness and manual dexterity in hand osteoarthritis. Ann Rheum Dis. 2002, 61: 1075-1080. 10.1136/ard.61.12.1075.PubMedCentralPubMed
3.
Creamer P, Hunt M, Dieppe P: Pain mechanisms in osteoarthritis of the knee: Effect of intra-articular anaesthetic. J Rheumatol. 1996, 23: 1031-1036.PubMed
4.
Crawford RW, Gie GA, Ling RS, Murray DW: Diagnostic value of intra-articular anaesthetic in primary osteoarthritis of the hip. J Bone Joint Surg Br. 1998, 80: 279-281. 10.1302/0301-620X.80B2.8299.PubMed
5.
Kosek E, Ordeberg G: Lack of pressure pain modulation by heterotopic noxious conditioning stimulation in patients with painful osteoarthritis before, but not following, surgical pain relief. Pain. 2000, 88: 69-78. 10.1016/S0304-3959(00)00310-9.PubMed
6.
Buffington ALH, Hanlon CA, McKeown MJ: Acute and persistent pain modulation of attention-related anterior cingulated fMRI activations. Pain. 2005, 113: 172-184. 10.1016/j.pain.2004.10.006.PubMed
7.
Rowbotham MC, Kidd BL, Porreca F: Role of central sensitization in chronic pain: Osteoarthritis and rheumatoid arthritis compared to neuropathic pain. Proceedings of the 11th World Congress on Pain. August 21 – 26th 2005, Sydney, Australia. Edited by: Flor H, Kalso E, Dostrovsky J. 2006, Seattle; IASP Press
8.
Fraenkel M, Bogardus ST, Concato J, Wittink DR: Treatment options in knee OA. Arch Intern Med. 2004, 164: 1299-1304. 10.1001/archinte.164.12.1299.PubMed
9.
Yaksh TL: Pharmacology and mechanisms of opioid analgesic activity. Acta Anaesthesiol Scand. 1997, 41: 94-111.PubMed
10.
Hurley RW, Hammond DL: The analgesic effects of supraspinal μ and δ opioid receptor agonists are potentiated during persistent inflammation. J Neurosci. 2000, 20: 1249-1259.PubMed
11.
Sawynok J: Topical and peripherally acting analgesics. Pharmacol Rev. 2003, 55: 1-20. 10.1124/pr.55.1.1.PubMed
12.
Likar R, Schafer M, Paulak F, Sittl R, Pipam W, Schalk H, Geissler D, Bernatzky G: Intraarticular morphine analgesia in chronic pain patients with osteoarthritis. Anesth Analg. 1997, 84: 1313-1317. 10.1097/00000539-199706000-00025.PubMed
13.
Menendez L, Lastra A, Meana A, Hidalgo A, Baamonde A: Analgesic effects of loperamide in bone cancer pain in mice. Pharmacol Biochem Behav. 2005, 81: 114-121. 10.1016/j.pbb.2005.02.007.PubMed
14.
Whiteside GT, Boulet JM, Walker K: The role of central and peripheral mu opioid receptors in inflammatory pain and edema: a study using morphine and DiPOA ([8-(3,3-diphenyl-propyl)-4-oxo-1-phenyl-1,3,8-triaza-spiro[4.5]dec-3-yl]-acetic acid). J Pharmacol Exp Ther. 2005, 314: 1234-1240. 10.1124/jpet.105.088351.PubMed
15.
Dray A: Alternatives to mu-opioid analgesics: delta-opioid and galanin-receptor selective compounds. Progress in Pain Research and Management. Edited by: Kalso E, McQuay HJ, Wiesenfeld-Hallin Z. 1999, Seattle: IASP Press, 269-280.
16.
Cahill CM, Morinville A, Lee M-C, Vincent J-P, Collier B, Beaudet A: Prolonged morphine treatment targets δ opioid receptors to neuronal plasma membranes and enhances δ-mediated antinociception. J Neurosci. 2001, 21: 7598-7607.PubMed
17.
Koblish M, LaBuda CJ, Ajello CW, Gu M, Zhou QJ, Tuthill PA, Chu G, Le Bourdonnec B, Dolle RE, Little PJ: Anti-hyperalgesic activity of a novel delta-opioid receptor agonist. Soc Neurosci Abst. 2005, 490.14-
18.
Dray A: Kinins and their receptors in hyperalgesia. Can J Physiol Pharmacol. 1997, 75: 704-712. 10.1139/cjpp-75-6-704.PubMed
19.
Dray A, Perkins MN: Bradykinin and inflammatory pain. Trends Neurosci. 1993, 16: 99-104. 10.1016/0166-2236(93)90133-7.PubMed
20.
Wotherspoon G, Winter J: Bradykinin B1 receptor is constitutively expressed in the rat sensory nervous system. Neurosci Lett. 2000, 294: 175-178. 10.1016/S0304-3940(00)01561-5.PubMed
21.
Shughrue PJ, Ky B, Austin CP: Localization of B1 bradykinin receptor mRNA in the primate brain and spinal cord: an in situ hybridization study. J Comp Neurol. 2003, 465: 372-384. 10.1002/cne.10846.PubMed
22.
Levy D, Zochodne DW: Increased mRNA expression of the B1 and B2 bradykinin receptors and antinociceptive effects of their antagonists in an animal model of neuropathic pain. Pain. 2000, 86: 265-271. 10.1016/S0304-3959(00)00256-6.PubMed
23.
Fox A, Wotherspoon G, McNair K, Hudson L, Patel S, Gentry C, Winter L: Regulation and function of spinal and peripheral neuronal B(1) bradykinin receptors in inflammatory mechanical hyperalgesia. Pain. 2003, 104: 683-691. 10.1016/S0304-3959(03)00141-6.PubMed
24.
Ferreira J, Beirith A, Mori MAS, Araujo RC, Bader M, Pesqero JB, Calixto JB: Reduced nerve injury induced neuropathic pain in kinin B1 receptor knock-out mice. J Neurosci. 2005, 25: 2405-2412. 10.1523/JNEUROSCI.2466-04.2005.PubMed
25.
Eisenbarth H, Rukwied R, Petersen M, Schmelz M: Sensitization to bradykinin B1 and B2 receptor activation in UV-B irradiated human skin. Pain. 2004, 110: 197-204. 10.1016/j.pain.2004.03.031.PubMed
26.
Vellani V, Zachrisson O, McNaughton PA: Functional bradykinin B1 receptors are expressed in nociceptive neurons and are upregulated by the neurotrophin GDNF. J Physiol. 2004, 560: 391-401. 10.1113/jphysiol.2004.067462.PubMedCentralPubMed
27.
Marceau F, Hess JF, Bachvarov DR: The B1 receptors for kinins. Pharmacol Rev. 1998, 50: 357-386.PubMed
28.
Liang YF, Haake B, Reeh PW: Sustained sensitization and recruitment of rat cutaneous nociceptors by bradykinin and a novel theory of its excitatory action. J Physiol. 2001, 532: 229-239. 10.1111/j.1469-7793.2001.0229g.x.PubMedCentralPubMed
29.
Fox A, Kaur S, Li B, Panasar M, Saha U, Davis C, Dragoni I, Colley S, Ritchie T, Bevan S, et al: Antihyperalgesic activity of a novel nonpeptide bradykinin B1 receptor antagonist in transgenic mice expressing the human B1 receptor. Br J Pharmacol. 2005, 144: 889-899. 10.1038/sj.bjp.0706139.PubMedCentralPubMed
30.
Stewart JM: Bradykinin antagonists: discovery and development. Peptides. 2004, 25: 527-732. 10.1016/j.peptides.2003.10.016.PubMed
31.
Burgess GM, Perkins MN, Rang HP, Campbell EA, Browen MC, McIntyre P, Urban L, Dziadulewicz EK, Ritchie TJ, Hallet A, et al: Bradyzide, a potent nonpeptide B2 bradykinin receptors antagonist with long lasting oral activity in animal models of inflammatory hyperalgesia. Br J Pharmacol. 2000, 129: 77-86. 10.1038/sj.bjp.0703012.PubMedCentralPubMed
32.
Gougat J, Ferrari B, Lionel S, Planchenault C, Poncelet M, Maruani J, Alonso R, Cudennec A, Croci T, Guagnini F, et al: SSR240612 [(2R)-2-[((3R0-3-(1,3-benzodiol-5-yl)-3-{[(6-methoxy-2-napthyl)sulfonyl]amino}propanoyl)amino]-3-(4-{[2R,6S)-2,6-dimethylpiperidyl]methyl}phenyl}-N-isoproyl-Nmethylpropana mide hydrochloride], a new nonpeptide antagonist of the bradykinin B1 receptor: biochemical and pharmacological characterization. J Pharmacol Exp Ther. 2004, 309: 661-669. 10.1124/jpet.103.059527.PubMed
33.
Gabra BH, Sirois P: Beneficial effects of chronic treatment with the selective bradykinin B1 receptor antagonists, R-715 and R-953, in attenuating streptozotocin-diabetic thermal hyperalgesia. Peptides. 2003, 24: 1131-1139. 10.1016/j.peptides.2003.06.003.PubMed
34.
Flechtenmacher J, Talke M, Veith D, Heil K, Gebauer A, Schoenharting M: Icatibant induces pain relief in patients with osteoarthritis of the knee. Proceedings of the 9th World Congress of the OsteoArthritis Research Society Internation (OARSI). Chicago. 12: P332-December 2–5 2004
35.
Fox A, Bevan S: Therapeutic potential of cannabinoid receptor agonists as analgesic agents. Expert Opin Investig Drugs. 2005, 14: 695-703. 10.1517/13543784.14.6.695.PubMed
36.
Rice ASC, Farquhar-Smith WP, Nagy I: Endocannabinoids and pain: spinal and peripheral analgesia in inflammation and neuropathy. Prostaglandins Leukot Essent Fatty Acids. 2002, 66: 243-256. 10.1054/plef.2001.0362.PubMed
37.
Mbvundula EC, Bunning RA, Rainsford KD: Arthritis and cannabinoids: HU-210 and Win-55,212-2 prevent IL-1alpha-induced matrix degradation in bovine articular chondrocytes in vitro. J Pharm Pharmacol. 2006, 58: 351-358. 10.1211/jpp.58.3.0009.PubMed
38.
Kreitzer Ac, Regeher WG: Retrograde signaling by endocannabinoids. Curr Opin Neurobiol. 2002, 12: 324-330. 10.1016/S0959-4388(02)00328-8.PubMed
39.
de Novellis V, Mariani L, Palazzo E, Vita D, Marabese I, Scafuro M, Rossi F, Maione S: Periaqueductal grey CB1 cannabinoid and metabotropic glutamate subtype 5 receptors modulate changes in rostral ventromedial medulla neuronal activities induced by subcutaneous formalin in the rat. Neuroscience. 2005, 134: 269-281. 10.1016/j.neuroscience.2005.03.014.PubMed
40.
Walker JM, Huang SM, Strangman NM, Tsou K, Sanudo-Pena MC: Pain modulation by release of the endogenous cannabinoid anandamide. Proc Natl Acad Sci USA. 1999, 96: 12198-12203. 10.1073/pnas.96.21.12198.PubMedCentralPubMed
41.
Campbell FA, Tramer MR, Carroll D, Reynolds DJ, Moore RA, McQuay HJ: Are cannabinoids an effective and safe treatment option in the management of pain? A quantitative systematic review. BMJ. 2001, 323: 13-16. 10.1136/bmj.323.7303.13.PubMedCentralPubMed
42.
Dyson A, Peacock M, Chen A, Courade J-P, Yaqoob , Groark A, Brain C, Loong Y, Fox A: Antihyperalgesic properties of the cannabinoid CT-3 in chronic neuropathic and inflammatory pain states in the rat. Pain. 2005, 116: 129-137. 10.1016/j.pain.2005.03.037.PubMed
43.
Richardson JD, Kilo S, Hargreaves KM: Cannabinoids reduce hyperalgesia and inflammation via interactions with peripheral CB1 receptors. Pain. 1998, 75: 111-119. 10.1016/S0304-3959(97)00213-3.PubMed
44.
Karst M, Salim K, Burstein S, Conrad I, Hoy L, Schneider U: Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: a randomized controlled trial. JAMA. 2003, 290: 1757-1762. 10.1001/jama.290.13.1757.PubMed
45.
Malan TP, Ibrahim MM, Lai J, Vanderah TW, Makriyannis A, Porreca F: CB2 cannabinoid receptor agonists: pain relief without psychoactive effects?. Curr Opin Pharmacol. 2003, 3: 62-67. 10.1016/S1471-4892(02)00004-8.PubMed
46.
Labuda CJ, Koblish M, Little PJ: Cannabinoid CB2 receptor agonist activity in the hindpaw incision model of postoperative pain. Eur J Pharmacol. 2005, 527: 172-175. 10.1016/j.ejphar.2005.10.020.PubMed
47.
Valenzano KJ, Tafesse L, Lee G, Harrison JE, Bulet JM, Gottshall SL, Mark L, Pearson MS, Miller W, Shan S, et al: Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy. Neuropharmacology. 2005, 48: 658-672. 10.1016/j.neuropharm.2004.12.008.PubMed
48.
Elmes SJR, Winyard LA, Medhurst A, Clayton SJ, Wilson NM, Kendall AW, Chapman V: Activation of CB1 and CB2 receptors attenuates the induction and maintenance of inflammatory pain in the rat. Pain. 2005, 118: 327-335. 10.1016/j.pain.2005.09.005.PubMed
49.
Sokal DM, Elmes SJR, Kendall DA, Chapman V: Intraplantar injection of anandamide inhibits mechanically-evoked responses of spinal neurons via activation of Cb2 receptors in anaesthetized rats. Neuropharmacology. 2003, 45: 404-411. 10.1016/S0028-3908(03)00195-3.PubMed
50.
Cravatt BF, Lichtman AH: The endogenous cannabinoid system and its role in nociceptive behavior. J Neurobiol. 2004, 61: 149-160. 10.1002/neu.20080.PubMed
51.
Cravatt BF, Demarest K, Patricelli MP, Bracey MH, Giang DK, Martin BR, Lichtman AH: Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolyse. Proc Natl Acad Sci USA. 2001, 98: 9371-9376. 10.1073/pnas.161191698.PubMedCentralPubMed
52.
Lichtman AH, Leung D, Shelton CC, Saghatelian A, Hardouin C, Boger DL, Cravatt BJ: Reversible inhibitors of fatty acid amide hydrolase that promote analgesia: evidence for an unprecedented combination of potency and selectivity. J Pharmacol Exp Ther. 2004, 311: 441-448. 10.1124/jpet.104.069401.PubMed
53.
Chang L, Luo L, Palmer JA, Sutton S, Wilson SJ, Barbier AJ, Breitenbucher JG, Chaplan SR, Webb M: Inhibition of fatty acid amide hydrolase produces analgesia by multiple mechanisms. Br J Pharmacol. 2006, 148: 102-113. 10.1038/sj.bjp.0706699.PubMedCentralPubMed
54.
Cichewicz DL, McCarthy EA: Antinociceptive synergy between D9 tetrahydrocannabinol and opioids after oral administration. J Pharmacol Exp Ther. 2003, 304: 1010-1015. 10.1124/jpet.102.045575.PubMed
55.
England S, Bevan S, Dougherty RJ: PGE2 modulate the tetrodotoxin-resistant sodium current in neonatal dorsal root ganglion neurons via the cyclic AMP-protein kinase A cascade. J Physiol. 1996, 495: 429-440.PubMedCentralPubMed
56.
Gold MS, Levine JD, Correa M: Modulation of TTX-R I Na by PKC and PKA and their role in PGE2-induced sensitization of rat sensory neurons in vitro. J Neurosci. 1998, 18: 10345-10355.PubMed
57.
Bar K-J, Natura G, Telleria-Diaz A, Tascher P, Vogel R, Vasques E, Schaible H-G, Ebersberger A: Changes in the effect of spinal prostaglandin E2 during inflammation: prostaglandin E9EP1-EP4) receptors in spinal nociceptive processing of input from the normal and inflamed knee joint. J Neurosci. 2004, 24: 642-651. 10.1523/JNEUROSCI.0882-03.2004.PubMed
58.
Yaksh TL, Dirig DM, Conway CM, Svensson C, Luo ZD, Isakson PC: The acute hyperalgesic action of non-steroidal, anti-inflammatory drugs and release of spinal prostaglandin E2 is mediated by the inhibition of constitutive spinal cyclooxygenase-2 (COX-2) but not COX-1. J Neurosci. 2001, 21: 5847-5853.PubMed
59.
Harvey RJ, Depner UB, Wassle H, Ahmadi S, Heidl C, Reinold H, Smart TG, Harvey K, Schultz B, Abo-Salem OM, et al: Gly α3: an essential target for spinal PGE2-mediated inflammatory pain sensitization. Science. 2004, 304: 884-887. 10.1126/science.1094925.PubMed
60.
Chandrasekharan NV, Dai H, Roos KLT, Evanson NK, Tomsik J, Elton TS, Simmons DL: COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: Cloning, structure, and expression. Proc Natl Acad Sci USA. 2002, 99: 13926-13931. 10.1073/pnas.162468699.PubMedCentralPubMed
61.
Mitchell JA, Warner TD: COX isoforms in the cardiovascular system: understanding the activities of non-steroidal anti-inflammatory drugs. Nat Rev Drug Discov. 2006, 5: 75-85. 10.1038/nrd1929.PubMed
62.
Jakobsson PJ, Thoen S, Morgenstern R, Samuelsson B: Identification of human prostaglandin E synthase: a microsomal, glutathione-dependent, inducible enzyme, constituting a potential novel drug target. Proc Natl Acad Sci USA. 1999, 96: 7220-7225. 10.1073/pnas.96.13.7220.PubMedCentralPubMed
63.
Claveau D, Sirinyan M, Guay J, Gordon R, Chan C-C, Bureau Y, Riendeau D, Mancini JA: Microsomal prostaglandin synnthase-1 is a major terminal synthase that is selectively upregulated during cyclooxygenase-2-dependent prostaglandin E2 production in the rat adjuvant-arthritis model. J Immunol. 2003, 170: 4738-4744.PubMed
64.
Trebino CE, Stock JL, Gibbons CP, Naiman BM, Wachtmann TS, Umland JP, Pandher K, Lapointe JM, Saha S, Roach ML, et al: Impaired inflammatory and pain responses in mice lacking an inducible prostaglandin E synthase. Proc Natl Acad Sci USA. 2003, 100: 9044-9049. 10.1073/pnas.1332766100.PubMedCentralPubMed
65.
Sommer C, Kress M: Recent findings on how proinflammatory cytokines cause pain: peripheral mechanisms in inflammatory and neuropathic hyperalgesia. Neurosci Lett. 2004, 361: 184-187. 10.1016/j.neulet.2003.12.007.PubMed
66.
Ohtori S, Takahashi K, Moriya H, Myers RR: TNF-alpha and TNF-alpha receptor type 1 upregulation in glia and neurons after peripheral nerve injury: studies in murine DRG and spinal cord. Spine. 2004, 29: 1082-1088. 10.1097/00007632-200405150-00006.PubMed
67.
Pollock J, McFarlane SM, Connell MC, Zehavi U, Vandenabeele P, MacEwan DJ, Scott RH: TNF-alpha receptors simultaneously activate Ca2+ mobilisation and stress kinases in cultured sensory neurons. Neuropharmacology. 2002, 42: 93-106. 10.1016/S0028-3908(01)00163-0.PubMed
68.
Schafers M, Marziniak M, Sorkin LS, Yaksh TL, Sommer C: Cyclooxygenase inhibition in nerve-injury- and TNF-induced hyperalgesia in the rat. Exp Neurol. 2004, 185: 160-168. 10.1016/j.expneurol.2003.09.015.PubMed
69.
Schafers M, Sorkin LS, Geis C, Shubayev VI: Spinal ligation induces transient upregulation of tumor necrosis factor receptors 1 and 2 in injured and adjacent uninjured dorsal root ganglia of rat. Neurosci Lett. 2003, 347: 179-182. 10.1016/S0304-3940(03)00695-5.PubMed
70.
Grunke M, Schulze-Koops H: Successful treatment of inflammatory knee osteoarthritis with tumour necrosis factor blockade. Ann Rheum Dis. 2006, 65: 555-556. 10.1136/ard.2006.053272.PubMedCentralPubMed
71.
Watkins LR, Maier S: Beyond neurons: evidence that immune and glial cells contribute to pathological pain states. Physiol Rev. 2002, 82: 981-1011.PubMed
72.
Zhang N, Inan S, Cowan A, Sun R, Wang JM, Rogers TJ, Caterina M, Oppenheim JJ: A proinflammatory chemokine, CCL3, sensitizes the heat- and capsaicin-gated ion channel TRPV1. Proc Natl Acad Sci USA. 2005, 102: 4536-4541. 10.1073/pnas.0406030102.PubMedCentralPubMed
73.
Oh SB, Tran PB, Gillard SE, Hurley RW, Hammond DL, Miller RJ: Chemokines and glycoprotein 120 produce pain hypersensitivity by directly exciting primary nociceptive neurons. J Neurosci. 2001, 21: 5027-5035.PubMed
74.
Weidler C, Holzer C, Harbuz M, Hofbauer R, Angele P, Scholmerich J, Straub RH: Low density of sympathetic nerve fibres and increased density of brain derived neurotrophic factor positive cells in RA synovium. Ann Rheum Dis. 2005, 64: 13-20. 10.1136/ard.2003.016154.PubMedCentralPubMed
75.
Miller LE, Wiedler C, Falk W, Angele P, Schaumberger J, Scholmerich J, Straub R: Increased prevalence of semaphorin3C, a repellent of sympathetic nerve fibres in synovial tissue of patients with rheumatoid arthritis. Arthritis Rheum. 2004, 50: 1156-1163. 10.1002/art.20110.PubMed
76.
Niissalo S, Hukkanen M, Imai S, Tornwall J, Konttinen YT: Neuropeptides in experimental and degenerative arthritis. Ann N Y Acad Sci. 2002, 966: 384-399.PubMed
77.
Zhang JM, LI H, Munir MA: Decreasing sympathetic sprouting in pathological sympathetic ganglia: a new mechanism for treating neuropathic pain using lidocaine. Pain. 2004, 109: 143-149. 10.1016/j.pain.2004.01.033.PubMed
78.
Shinder V, Govrin-Lippmann R, Cohen S, Belenky M, Ilin P, Fried K, Wilkinson HA, Devor M: Structural basis of sympathetic-sensory coupling in rat and human dorsal root ganglia following peripheral nerve injury. J Neurocytol. 1999, 28: 743-761. 10.1023/A:1007090105840.PubMed
79.
Sato J, Perl ER: Adrenergic excitation of cutaneous pain receptors induced by peripheral nerve injury. Science. 1991, 251: 1608-1610. 10.1126/science.2011742.PubMed
80.
Lee DH, Liu X, Kim HT, Chung K, Chung JM: Receptor subtype mediating the adrenergic sensitivity of pain behavior and ectopic discharges in neuropathic Lewis rats. J Neurophysiol. 1999, 81: 2226-2233.PubMed
81.
Ali Z, Raja SN, Wesselmann U, Fuchs PN, Meyer RA, Campbell JN: Intradermal injection of norepinephrine evokes pain in patients with sympathetically maintained pain. Pain. 2000, 88: 161-168. 10.1016/S0304-3959(00)00327-4.PubMed
82.
McNearney T, Baethge BA, Cao S, Alam R, Lisse JR, Westlund KN: Excitatory amino acids, TNFα and chemokine levels in synovial fluids of patients with active arthropathies. Clin Exp Immunol. 2004, 137: 621-627. 10.1111/j.1365-2249.2004.02563.x.PubMedCentralPubMed
83.
Neugebauer V: Glutamate receptor ligands. Handb Exp Pharmacol. 2007, 177: 217-249.PubMed
84.
Szekely JI, Torok K, Mate G: The role of ionotropic glutamate receptors in nociception with special regard to the AMPA binding sites. Curr Pharm Des. 2002, 8: 887-912. 10.2174/1381612024607126.PubMed
85.
Merle B, Itzstein C, Delmas PD, Chenu C: NMDA glutamate receptors are expressed by osteoclast precursors and involved in the regulation of osteoclastogenesis. J Cell Biochem. 2003, 90: 424-436. 10.1002/jcb.10625.PubMed
86.
Salter DM, Wright MO, Millward-Sadler SJ: NMDA receptor expression and roles in human articular chondrocyte mechanotransduction. Biorheology. 2004, 41: 273-281.PubMed
87.
Danysz W, Parsons CG: GlycineB recognition site of NMDA receptors and its antagonists. Amino Acids. 1998, 14: 205-206. 10.1007/BF01345263.PubMed
88.
Quartaroli M, Fasdelli N, Bettelini L, Maraia G, Corsi M: GV196771A, an NMDA receptor/glycine site antagonist, attenuates mechanical allodynia in neuropathic rats and reduces tolerance induced by morphine in mice. Eur J Pharmacol. 2001, 430: 219-227. 10.1016/S0014-2999(01)01278-X.PubMed
89.
Wallace MS, Rowbotham MC, Katz NP, Dworkin RH, Dotson RM, Galer BS, Rauck RL, Backonja MM, Quessy SN, Meisner PD: A randomized, double blind, placebo-controlled trial of a glycine antagonist in neuropathic pain. Neurology. 2002, 59: 1694-1700.PubMed
90.
Taniguchi K, Shinjo K, Mizutani M, Shimada K, Ishikawa T, Menniti F, Nagahisa A: Antinociceptive actions of CP-101,606, an NMDA receptor NR2B subunit antagonist. Br J Pharmacol. 1997, 122: 809-812. 10.1038/sj.bjp.0701445.PubMedCentralPubMed
91.
Hudson LJ, Bevan S, McNair K, Gentry C, Fox A, Kuhn R, Winter J: Metabotropic glutamate receptor 5 up-regulation in A-fibers after spinal nerve injury: 2-Methyl-6-(phenylethynyl)-pyridine (MPEP) reverses the induced thermal hyperalgesia. J Neurosci. 2002, 22: 2660-2668.PubMed
92.
Dogrul A, Ossipov MH, Lai J, Malan TP, Porecca F: Peripheral and spinal antihyperalgesic activity of SIB-1757, a metabotropic glutamate receptor (mGluR5) antagonist, in experimental neuropathic pain in rats. Neurosci Lett. 2000, 292: 115-118. 10.1016/S0304-3940(00)01458-0.PubMed
93.
Zhu CZ, Wilson SG, Mikusa JP, Wismer CT, Gauvin DM, Lynch JJ, Wade CL, Decker MW, Honore P: Assessing the role of metabotropic glutamate receptor 5 in multiple nociceptive modalities. Eur J Pharmacol. 2004, 506: 107-118. 10.1016/j.ejphar.2004.11.005.PubMed
94.
Boxall SJ, Berthele A, Laurie DJ, Sommer B, Zieglgansberger W, Urban L, Tolle TR: Enhanced expression of metabotropic glutamate receptor 3 messenger RNA in the rat spinal cord during ultraviolet irradiation induced peripheral inflammation. Neuroscience. 1998, 82: 591-602. 10.1016/S0306-4522(97)00246-7.PubMed
95.
Chiechio S, Caricasole A, Barletta E, Storto M, Catania MV, Copani A, Vertechy M, Nicolai R, Calvani M, Melchiorri D, Nicoletti F: L-Acetylcarnitine induces analgesia by selectively upregulating mGlu2 metabotropic glutamate receptors. Mol Pharmacol. 2002, 61: 989-996. 10.1124/mol.61.5.989.PubMed
96.
Vellani V, Mappleback S, Moriondo A, Davis JB, McNaughton PA: Protein kinase C activation gating of the vanilloid receptor VR1 by capsaicin, protons, heat and anandamide. J Physiol. 2001, 534: 813-825. 10.1111/j.1469-7793.2001.00813.x.PubMedCentralPubMed
97.
Szallasi A, Blumberg PM: Vanilloid (Capsaicin) receptors and mechanisms. Pharmacol Rev. 1999, 51: 159-212.PubMed
98.
Cantillon M, Vause E, Sykes D, Moon A, Hughes S: Safety, tolerability and efficacy of ALGRX 4975 in osteoarthritis (OA) of the knee. Journal of Pain. 2005, 6 (3): S39-
99.
Garcia-Martiez C, Humet M, Planells-Casas R, Gomis A, Capri M, Viaa F, de la Pena E, Sachez-Baez F, Carbonell T, de Felipe C, et al: Attenuation of thermal nociception and hyperalgesia by VR1 blockers. Proc Natl Acad Sci USA. 2002, 99: 2374-2379. 10.1073/pnas.022285899.
100.
Gavva NR, Tamir R, Qu Y, Klionsky L, Zhang TJ, Immke D, Wang J, Zhu D, Vanderah TW, Porreca F, Doherty EM, et al: AMG 9810 [(E)-3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo[b][1,4] dioxin-6-yl)acrylamide], a novel vanilloid receptor 1 (TRPV1) antagonist with antihyperalgesic properties. J Pharmacol Exp Ther. 2005, 313: 474-484. 10.1124/jpet.104.079855.PubMed
101.
Chizh B, Napolitano A, O'Donnell M, Wang J, Brooke A, Lai R, Aylott M, Bullman J, Gray E, Williams P, Appleby J: The TRPV1 antagonist SB705498 attenuates TRPV1 receptor mediated activity and inhibits inflammatory hyperalgesia in humans: Results from a Phase 1 study. Journal of Pain. 2006, 7 (4): S42-
102.
Bandell M, Story GM, Hwang SW, Viswanath V, Eid SR, Petrus MJ, Earley TJ, Pataapouian A: Noxious cold ion channel TRPA1 is activated by pungent compounds and bradykinin. Neuron. 2004, 41: 849-853. 10.1016/S0896-6273(04)00150-3.PubMed
103.
Bland-Ward PA, Humphrey PP: P2x receptor mediated ATP-induced primary nociceptive neurone activation. J Auton Nerv Syst. 2000, 81: 146-151. 10.1016/S0165-1838(00)00122-3.PubMed
104.
Honore P, Kage K, Mikusa J, Watt AT, Johnston JF, Wyatt JR, Faltynek CR, Jarvis MF, Lynch K: Analgesic profile of intrathecal P2X(3) antisense oligonucleotide treatment in chronic inflammatory and neuropathic pain states in rats. Pain. 2002, 99: 11-19. 10.1016/S0304-3959(02)00032-5.PubMed
105.
Jarvis MF, Burgard EC, McGaraughty S, Honore P, Lynch K, Brennan TJ, Subieta A, van Biesen T, Cartmell J, Bianchi B, et al: A-317491, a novel potent and selective non nucleotide antagonist of P2X(3) and P2X(2/3) receptors, reduces chronic inflammatory and neuropathic pain in the rat. Proc Natl Acad Sci USA. 2002, 99: 17179-17184. 10.1073/pnas.252537299.PubMedCentralPubMed
106.
Tsuda M, Shigemoto-Mogami Y, Koizumi S, Mizokoshi A, Kohsaka S, Salter MW, Inoue K: P2X4 receptors induced in spinal microglia gate tactile allodynia after nerve injury. Nature. 2003, 424: 778-783. 10.1038/nature01786.PubMed
107.
Deuchars SA, Atkinson L, Brooke RE, Musa H, Milligan CJ, Batten TFC, Buckley NJ, Parson SH, Deuchars J: Neuronal P2X7 receptors are targeted to presynaptic terminals in the central and peripheral nervous systems. J Neurosci. 2001, 21: 7143-7152.PubMed
108.
Chessell IP, Hatcher JP, Bountra C, Michel AD, Hughes JP, Green P, Egerton J, Murfin M, Richardson J, Peck WL, et al: Disruption of the P2X7 purinoceptor gene abolishes chronic inflammatory and neuropathic pain. Pain. 2005, 114: 386-396. 10.1016/j.pain.2005.01.002.PubMed
109.
Chaplan SR, Guo H-Q, Lee DH, Luo L, Liu C, Kuei C, Velumian AAL, Butler MP, Brown SM, Dubin AE: Neuronal hyperpolarization-activated pacemaker channels drive neuropathic pain. J Neurosci. 2003, 23: 1169-1178.PubMed
110.
Yao H, Donnelly DF, Ma C, LaMotte RH: Upregulation of the hyperpolarization activation cation current after chronic compression of the dorsal root ganglion. J Neurosci. 2003, 23: 2069-2074.PubMed
111.
Giatromanolaki A, Sivridis E, Maltezos E, Athanassou N, Papazoglou D, Gatter KC, Harris AL, Koukourakis MI: Upregulated hypoxia inducible factor-1alpha and -2alpha pathway in rheumatoid arthritis and osteoarthritis. Arthritis Res Ther. 2003, 5: R193-201. 10.1186/ar756.PubMedCentralPubMed
112.
Leffler A, Monter B, Koltzenburg M: The role of the capsaicin receptor TRPV1 and acid sensing ion channels (ASICs) in proton sensitivity of subpopulation of primary nociceptive neurons in rats and mice. Neuroscience. 2006, 139: 699-709. 10.1016/j.neuroscience.2005.12.020.PubMed
113.
Dube GR, Lehto SG, Breese NM, Baker SJ, Wang X, Matulenko MA, Honore P, Stewart AO, Moreland RB, Brioni JD: Electrophysiological and in vivo characterization of A-317567, a novel blocker of acid sensing ion channels. Pain. 2005, 117: 88-96. 10.1016/j.pain.2005.05.021.PubMed
114.
Matzner O, Devor M: Hyperexcitability at sites of nerve injury depends on voltage sensitive sodium channels. J Neurophysiol. 1994, 72: 349-359.PubMed
115.
Eglen RM, Hunter JC, Dray A: Ions in the fire: recent ion-channel research and approaches to pain therapy. Trends Pharmacol Sci. 1999, 8: 337-342. 10.1016/S0165-6147(99)01372-3.
116.
Devor M: Sodium channels and mechanisms of neuropathic pain. Pain. 2005, 7 (Suppl 1): S3-S12.
117.
Waxman SG, Dib-Hajj S: Erythermalgia: molecular basis for an inherited pain syndrome. Trends Mol Med. 2005, 11: 555-562. 10.1016/j.molmed.2005.10.004.PubMed
118.
Gould HJ, England JD, Soignier RD, Nolan P, Minor LD, Liu ZP, Levinson SR, Paul D: Ibuprofen blocks changes in NaV1.7 and 1.8 sodium currents associated with complete Freunds adjuvant induced inflammation in rat. Pain. 2004, 5: 270-280. 10.1016/j.jpain.2004.04.005.
119.
Araujo MC, Sinnott CJ, Strichartz GR: Multiple phases of relief from experimental mechanical allodynia by systemic lidocaine: responses to early and late infusions. Pain. 2003, 103: 21-29. 10.1016/S0304-3959(02)00350-0.PubMed
120.
Kastrup J, Petersen P, Dejgard A, Angelo FR: Intravenous lidocaine infusion: a new treatment of chronic painful diabetic neuropathy. Pain. 1987, 28: 69-75. 10.1016/0304-3959(87)91061-X.PubMed
121.
Okuse K, Malik-Hall M, Baker MD, Poon W-YL, Chao MV, Wood JN: Annexin II light chain regulates sensory neurone-specific sodium channel expression. Nature. 2002, 417: 653-656. 10.1038/nature00781.PubMed
122.
Rush AM, Craner MJ, Kageyama T, Dib-Haj SD, Waxman SG: Contactin regulates the current density and axonal expression of tetrodotoxin-resistant but not tetrodotoxin-sensitive sodium channels in DRG neurons. Eur J Neurosci. 2005, 22: 39-49. 10.1111/j.1460-9568.2005.04186.x.PubMed
123.
Yaksh TL: Calcium channels as therapeutic targets in neuropathic pain. J Pain. 2006, 7 (1 Suppl 1): S13-S30. 10.1016/j.jpain.2005.09.007.PubMed
124.
Altier C, Khosravani H, Evans RM, Hameed S, Peloquin JB, Vartian BA, Chen L, Beedle AM, Ferguson SS, Mezghrani A, et al: ORL-1 receptor mediated internalization of N-type calcium channels. Nat Neurosci. 2005, 9: 31-40. 10.1038/nn1605.PubMed
125.
Kim C, Jun K, Lee T, Kim SS, McEnery MW, Chin H, Kim HL, Park JM, Kim DK, Jung SJ, Kim J, Shin HS: Altered nociceptive response in mice deficient in the α(1B) subunit of the voltage-dependent calcium channel. Mol Cell Neurosci. 2001, 18: 235-245. 10.1006/mcne.2001.1013.PubMed
126.
Saegusa H, Kurihara T, Zong S, Kazuno A, Matsuda Y, Nonaka T, Han W, Toriyama H, Tanabe T: Suppression of inflammation and neuropathic pain symptoms in mice lacking the N-type Ca2+ channel. EMBO J. 2001, 20: 2349-2356. 10.1093/emboj/20.10.2349.PubMedCentralPubMed
127.
Xiao WH, Bennett GJ: Synthetic omega-conopeptides applied to the site of nerve injury suppress neuropathic pains in rats. J Pharmacol Exp Ther. 1995, 274: 666-672.PubMed
128.
Snutch TP: Targeting chronic and neuropathic pain: the N-type calcium channel comes of age. NeuroRx. 2005, 2: 662-670. 10.1602/neurorx.2.4.662.PubMedCentralPubMed
129.
Ikeda H, Heinke B, Ruscheweyh R, Sandkuhler J: Synaptic plasticity in spinal lamina 1 projection neurons that mediate hyperalgesia. Science. 2003, 299: 1237-1240. 10.1126/science.1080659.PubMed
130.
Matthews EA, Dickenson AH: Effects of spinally delivered N-and P-type voltage dependent calacium channel antagonists on dorsal horn neuronal responses in a rat model of neuropathy. Eur J Pharmacol. 2001, 415: 141-149. 10.1016/S0014-2999(01)00812-3.PubMed
131.
Flatters SJ, Bennett GJ: Ethosuximaide reverses paclitaxel and vincristine-induced painful peripheral neuropathy. Pain. 2004, 109: 150-161. 10.1016/j.pain.2004.01.029.PubMed
132.
Lu Y, Westlund KN: Gabapentin attenuates nociceptive behaviours in an acute arthritis model in rats. J Pharmacol Exp Ther. 1999, 290: 214-219.PubMed
133.
Luo ZD, Calcutt NA, Higuera ES, Valder CR, Song YH, Svensson CI, Myers RR: Injury type-specific calcium channel alpha (2) delta-1 subunit up-regulation in rat neuropathic pain models correlates with antiallodynic effects of gabapentin. J Pharmacol Exp Ther. 2002, 303: 1199-1205. 10.1124/jpet.102.041574.PubMed
134.
Jaffe M, Iacobellis D, Young JP, et al: Post-hoc results show beneficial effects of pre-gabalin in patients with osteoarthritis of the hip. Arthritis Rheum. 2000, 43 (Suppl): S337-
135.
Sah DWY, Ossipov MH, Porecca F: Neurotrophic factors as novel therapeutics for neuropathic pain. Nat Rev Drug Discov. 2003, 2: 460-472. 10.1038/nrd1107.PubMed
136.
Zweifel LS, Kuruvilla R, Ginty DD: Functions and mechanisms of retrograde neurotrophin signaling. Nat Rev Neurosci. 2005, 6: 615-625. 10.1038/nrn1727.PubMed
137.
Lu B, Pang PT, Woo NH: The Yin and Yang of neurotrophin action. Nat Rev Neurosci. 2005, 6: 603-614. 10.1038/nrn1726.PubMed
138.
Ro LS, Chen ST, Tang LM, Jacobs JM: Effect of NGF and anti-NGF on neuropathic pain in rats following chronic constriction injury of the sciatic nerve. Pain. 1999, 79: 265-274. 10.1016/S0304-3959(98)00164-X.PubMed
139.
Theodosiou M, Rush RA, Zhou XF, Hu D, Walker JS, Tracey DJ: Hyperalgesia due to nerve damage: role of nerve growth factor. Pain. 1999, 81: 245-255. 10.1016/S0304-3959(99)00018-4.PubMed
140.
Hefti FF, Rosenthal A, Walicka PA, Wyatt S, Vergara G, Shelton DL, Davis AM: Novel class of pain drug based on antagonism of NGF. Trends Pharmacol Sci. 2005, 27: 85-91. 10.1016/j.tips.2005.12.001.PubMed
141.
Ji RR, Samad TA, Jin SX, Schmoll R, Woolf CJ: P38 MAPK activation by NGF in primary sensory neurons after inflammation increases TRPV1 levels and maintains heat hyperalgesia. Neuron. 2002, 36: 57-68. 10.1016/S0896-6273(02)00908-X.PubMed
142.
Fjell J, Cummings TR, Fried K, Black JA, Waxman SG: In vivo NGF deprivation reduces SNS expression and TTX-R sodium currents in IB4-negative DRG neurons. J Neurophysiol. 1999, 81: 803-810.PubMed
143.
Mamet J, Lazdunski M, Voilley N: How nerve growth factor drives physiological and inflammatory expression of acid-sensing ion channels 3 in sensory neurons. J Biol Chem. 2003, 278: 48907-48913. 10.1074/jbc.M309468200.PubMed
144.
Petersen M, Segond von Banchet G, Heppelmann B, Koltzenburg M: Nerve growth factor regulates the expression of bradykinin binding sites on adult sensory neurons via the neurotrophin receptor p75. Neuroscience. 1998, 83: 161-168. 10.1016/S0306-4522(97)00374-6.PubMed
145.
Ramer MS, Bradbury EJ, McMahon SB: Nerve growth factor induces P2X(3) expression in sensory neurons. J Neurochem. 2001, 77: 864-875. 10.1046/j.1471-4159.2001.00288.x.PubMed
146.
Oddiah D, Anand P, McMahon SB, Rattray M: Rapid increase of NGF, BDNF and NT3 mRNAs in inflamed bladder. NeuroReport. 1998, 9: 1455-1458. 10.1097/00001756-199805110-00038.PubMed
147.
Miller LJ, Fischer KA, Goralnick SJ, Litt M, Burleson JA, Albertsen P, Kreutzer DL: Nerve growth factor and chronic prostatis/chronic pelvic pain syndrome. Urology. 2002, 59: 603-608. 10.1016/S0090-4295(01)01597-7.PubMed
148.
Aloe L, Tuveri MA, Carcassi U, Levi-Montalcini R: Nerve growth factor in the synovial fluid of patients with chronic arthritis. Arthritis Rheum. 1992, 35: 351-355. 10.1002/art.1780350315.PubMed
149.
Halliday DA, Zettler C, Rush RA, Scicchitano R, McNeil JD: Elevated growth factor levels in the synovial fluid of patients with inflammatory joint disease. Neurochem Res. 1998, 23: 919-922. 10.1023/A:1022475432077.PubMed
150.
Sarchielli P, Alberti A, Floridi A, Gallai V: Levels of nerve growth factor in cerebrospinal fluid of chronic headache patients. Neurology. 2001, 57: 132-134.PubMed
151.
Andreev N, Dimitrieva N, Kolzenburg M, McMahon SB: Peripheral administration of nerve growth factor in the adult rat produces a thermal hyperalgesia that requires the presence of sympathetic post-ganglionic neurones. Pain. 1995, 63: 109-115. 10.1016/0304-3959(95)00024-M.PubMed
152.
Apfel SC: Nerve growth factor for the treatment of diabetic neuropathy: what went wrong, what went right, and what does the future hold?. Int Rev Neurobiol. 2002, 50: 393-413.PubMed
153.
Sah DWY, Ossipov MH, Porecca F: Neurotrophic factors as novel therapeutics for neuropathic pain. Nat Rev Drug Discov. 2003, 2: 460-472. 10.1038/nrd1107.PubMed
154.
Owolabi JB, Rizkalla G, Tehim A, Ross GM, Riopelle RJ, Kamboj R, Ossipov M, Bianm D, Wegert S, Porreca F, Lee DK: Characterization of antiallodynic actions ALE-0540, a novel nerve growth factor receptor antagonist, in the rat. J Pharmacol Exp Ther. 1999, 289: 1271-1276.PubMed
155.
Colquhoun A, Lawrance GM, Shamovsky IL, Riopelle RJ, Ross GM: Differential activity of the nerve growth factor (NGF) antagonist PD90780 [7-benzoylamino)-4,9-dihydro-4methyl-8-oxo-pyrazolo-[5,1-b]-quinazoline-2-carboxylic acid] suggest altered NGF-p75NTR interactions in the presence of trkA. J Pharmacol Exp Ther. 2004, 310: 505-511. 10.1124/jpet.104.066225.PubMed
156.
Lane N, Webster L, Shiaoping Lu, Gray M, Hefti F, Walicke P: RN624 (anti-NGF) improves pain and function in subjects with moderate knee osteoarthritis: a phase i study. Arthritis Rheum. 2005, 52 (Suppl): S461-10.1002/art.20791.
157.
Coull JA, Beggs S, Boudreau D, Boivin D, Tsuda M, Inoue K, Gravel C, Salter MW, De Koninck Y: BDNF from microglia causes the shift in neuronal anion gradient underlying neuropathic pain. Nature. 2005, 438: 1017-1021. 10.1038/nature04223.PubMed
158.
Kerr BJ, Bradbury EJ, Bennett DL, Trivedi PM, Dassan P, French J, Shelton DB, McMahon SB, Thompson SW: Brain derived neurotrophic factor modulates nociceptive sensory neurone input and NMDA-evoked responses in the rat spinal cord. J Neurosci. 1999, 19: 5138-5148.PubMed
159.
Deng YS, Zhong JH, Zhou XF: Effects of endogenous neurotrophin on sympathetic sprouting in the dorsal root ganglia and allodynia following spinal nerve injury. Exp Neurol. 2000, 164: 344-350. 10.1006/exnr.2000.7432.PubMed
160.
Nutt JG, Burchiel KJ, Comella CL, Jankovic J, Lang AE, Laws ER, Lozano AM, Penn RD, Simpson RK, Stacy M, Wooten GF: ICV GDNF Study Group. Implanted intracerebroventricular. Glial cell line-derived neurotrophic factor. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology. 2003, 60: 69-73.PubMed
161.
Welch MJ, Purkiss JR, Foster KA: Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon. 2000, 38: 245-258. 10.1016/S0041-0101(99)00153-1.PubMed
162.
Mense S: Neurobiological basis for the use of botulinum toxin in pain therapy. J Neurol. 2004, 251 (Suppl 1): I1-I7. 10.1007/s00415-004-1102-z.PubMed
163.
Mahowald ML, Singh JA, Dykstra D: Long term effects of intra-articular botulinum toxin A for refractory joint pain. Neurotox Res. 2006, 9: 179-188.PubMed
164.
Apostolidis A, Popat R, Yiangou Y, Cockyne D, Ford ABDW, Davis JB, Dasgupta P, Fowler CJ, Anand P: Decreased sensory receptors P2X (3) and TRPV1 in suburothelial nerve fibers following intradetrusor injection of botulinum toxin for human detrusor overactivity. J Urol. 2005, 174: 977-982. 10.1097/01.ju.0000169481.42259.54.PubMed
165.
D'Amour FE, Smith DL: A method for determining loss of pain sensation. J Pharmacol Exp Ther. 1941, 72: 74-79.
166.
Woolfe G, MacDonald AD: The evaluation of the analgesic action of pethidine hydrochloride (Demerol). J Pharmacol Exp Ther. 1944, 80: 300-307.
167.
Le Bars D, Gozariu M, Cadden SW: Animal models of nociception. Pharmacol Rev. 2001, 53: 597-652.PubMed
168.
Felson DT, Chaisson CE, Hill CL, Totterman SM, Gale ME, Skinner KM, Kazis L, Gale DR: The association of bone marrow lesions with pain in knee osteoarthritis. Ann Intern Med. 2001, 134: 541-549.PubMed
169.
Hill CL, Gale DG, Chaisson CE, Skinner K, Kazis L, Gale ME, Felson DT: Knee effusions, popliteal cysts and synovial thickening: association with knee pain in osteoarthritis. J Rheumatol. 2001, 28: 1330-1337.PubMed
170.
Wluka AE, Wolfe R, Stuckey R, Cicuttini FM: How does tibial cartilage volume relate to symptoms in subjects with knee osteoarthritis?. Ann Rheum Dis. 2004, 63: 264-268. 10.1136/ard/2003.007666.PubMedCentralPubMed
171.
Van Der Kraan OM, Vitters EL, van de Putte LBA, van den Berg WB: Development of osteoarthritic lesions in mice by "metabolic" and "mechanical" alterations in the knee joints. Am J Pathol. 1989, 135: 1001-1014.PubMedCentralPubMed
172.
Clarke KA, Heitmeyer SA, Smith AG, Taiwo YO: Gait analysis in a rat model of osteoarthritis. Physiol Behav. 1997, 62: 951-954. 10.1016/S0031-9384(97)00022-X.PubMed
173.
Ivanavicius SP, Ball AD, Heapy CG, Westwood FR, Murray F, Read SJ: Structural pathology in a rodent model of osteoarthritis is associated with neuropathic pain: Increased expression of ATF-3 and pharmacological characterization. Pain. 2007
174.
Bove SE, Calcaterra SL, Brooker RM, Huber CM, Guzman RE, Juneau PL, Schrier DJ, Kilgore KS: Weight bearing as a measure of disease progression and efficacy of anti-inflammatory compounds in a model of monosodium iodoacetate-induced osteoarthritis. Osteoarthritis Cartilage. 2003, 11: 821-830. 10.1016/S1063-4584(03)00163-8.PubMed
175.
Fernihough J, Gentry C, Malcangio M, Fox A, Rediske J, Pellas T, Kidd B, Bevan S, Winter J: Pain releated behaviour in two model of osteoarthritis in the rat knee. Pain. 2004, 112: 83-93. 10.1016/j.pain.2004.08.004.PubMed
176.
Pomonis JDM, Boulet JM, Gottshall SL, Phillips S, Rani S, Bunton T, Walker K: Development and pharmacological characterization of a rat model of osteoarthritis pain. Pain. 2005, 114: 339-346. 10.1016/j.pain.2004.11.008.PubMed
Metadata
Title
Arthritis and pain. Future targets to control osteoarthritis pain
Authors
Andy Dray
Simon J Read
Publication date
01-06-2007
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 3/2007
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar2178

Other articles of this Issue 3/2007

Arthritis Research & Therapy 3/2007 Go to the issue

Editorial

Inflammatory cells and bone loss in rheumatoid arthritis

Review

Current status of lupus genetics

Review

Arthritis and pain. Current approaches in the treatment of arthritic pain

Research article

Hypoxic conditions increase hypoxia-inducible transcription factor 2α and enhance chondrogenesis in stem cells from the infrapatellar fat pad of osteoarthritis patients

Research article

Pro-apoptotic Bid is required for the resolution of the effector phase of inflammatory arthritis

Research article

Regulation of the JNK pathway by TGF-beta activated kinase 1 in rheumatoid arthritis synoviocytes

ACC 2024 Congress Coverage

Cardiology Video

Highlights from the ACC 2024 Congress

Watch now

Watch official videos from the ACC congress summarizing key highlights from the last year in heart failure, cardiomyopathies, valvular disease, pulmonary vascular disease, and pediatric cardiology.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits